Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymalin

Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique

Quick Stats
Studies 202
Trials 37
Score 1
1999 pubmed

[Effect of immunomodulators of varying nature on the expression of lymphocyte markers in melanoma patients].

Zaporozhets. T S TS; Likhobabin. V Ia VIa; Besednova. N N NN; Ermolenko. M V MV; Kiseleva. S M SM

Key Findings

  • Thymalin and similar immunomodulators can change lymphocyte marker expression in melanoma patients in vitro
  • The magnitude of change varies between individuals and depends on the initial level of those markers
  • Knowing a person’s cellular sensitivity might help design personalized immune‑support therapies, but no concrete treatment plan is offered

Practical Outcomes

  • For the biohacker community this study offers little direct action. It suggests thymalin could have immune‑modulating effects, but without human trials, dosing guidance, or safety data it isn’t ready for self‑experimentation or longevity protocols.

Summary

The paper tested thymalin and a few other immune‑boosting compounds on blood cells from melanoma patients in a lab dish and found that each person’s cells reacted differently, depending on their starting immune marker levels. It doesn’t give any dosing advice or proven benefits for healthy people, so it’s mostly a preliminary observation rather than a usable protocol.

Abstract

The influence of immunomodulators such as tactivin, thymalin, gangliin and translam on expression of lymphocyte markers in patients with melanoma was studied. It was shown in vitro that sensitivity of the lymphocyte receptors of melanoma patients to the immunomodulators was individual and depended on the initial level of the marker expression and the drug properties. Preliminary determination of sensitivity of the immunoregulatory cells to the immunomodulators lays the basis for the use of adequate immunocorrecting therapy in the complex treatment of oncologic patients. Gangliin and translam are membrane active compounds influencing the structure and function of lymphocytic membranes. They are considered as a promising class of immunomodulators with diverse spectra of immunotropic action and various fields of practical use.

Study Information

Provider

pubmed

Year

1999